Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
3.4
Journals
Vaccines
Special Issues
Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases
share announcement

Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccination Against Cancer and Chronic Diseases".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 1852

Special Issue Editors

Dr. Emmanuel Datan

E-Mail
Guest Editor
Vascular Program, Institute for Cell Engineering and Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Interests: gene transcription in oxygen biology; autophagy; ubiquitin-proteosome system; cell signaling; influenza virus; dengue virus; program cell death; epigenetics; drug discovery and development; chemical biology
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Athanasios Tsakris

E-Mail Website
Guest Editor
Department of Microbiology, Medical School University of Athens, Athens, Greece
Interests: mechanisms of resistance to antimicrobials; respiratory viruses; coronaviruses; laboratory diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Emerging viral infections continue to pose serious global health hazards, frequently resulting in extensive epidemics with limited therapeutic options. The fast development and adaptation of viruses emphasizes the critical need for novel ways to prevent and treat them. To this end, recombinant vaccination technologies and enhanced immunotherapy tactics have emerged as promising approaches to overcoming these obstacles.

This Special Issue aim to highlight innovative studies and reviews which focus on the development of recombinant vaccines and newly developed immunotherapeutic treatments for re-emerging viral infections. Topics of interest include novel vaccine platforms (such as viral vectors, DNA/RNA-based vaccines, and protein subunit vaccines), advancements in antibody therapies, immune modulation techniques, and strategies for enhancing vaccine efficacy against highly mutable viruses.

Dr. Emmanuel Datan
Prof. Dr. Athanasios Tsakris
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • emerging viral diseases
  • recombinant vaccines
  • immunotherapy
  • vaccine development
  • immune modulation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 277 KB  
Article
Global Health Preparedness Frameworks and Recombinant Vaccine Platforms: A Public Health Perspective on Regulations and System Readiness
by Luigi Russo, Leonardo Villani, Roberto Ieraci and Walter Ricciardi
Vaccines 2026, 14(2), 144; https://doi.org/10.3390/vaccines14020144 - 30 Jan 2026
Viewed by 1206
Abstract
Background/objectives. Emerging viral diseases represent an increasing threat to global health security, driven by environmental change, globalization, and intensified human–animal–environment interactions. The COVID-19 pandemic exposed critical weaknesses in preparedness systems but also demonstrated the transformative potential of recombinant vaccine technologies, which enable rapid, [...] Read more.
Background/objectives. Emerging viral diseases represent an increasing threat to global health security, driven by environmental change, globalization, and intensified human–animal–environment interactions. The COVID-19 pandemic exposed critical weaknesses in preparedness systems but also demonstrated the transformative potential of recombinant vaccine technologies, which enable rapid, scalable, and safe responses to novel pathogens. We aim to examine the role of recombinant vaccine platforms in the management of emerging viral diseases, emphasizing their contribution to health system preparedness and exploring strategies for their integration into preparedness frameworks. Methods. We synthesized the current evidence on recombinant vaccine platforms (viral vector, protein subunit, DNA, and mRNA) through a targeted review of the scientific literature, regulatory documents, and global health policy reports. Drawing from experiences like COVID-19 (mRNA vaccines) and Ebola (rVSV-ZEBOV), we analyzed the advantages, challenges, and lessons from initiatives such as the CEPI, BARDA, HERA, and WHO frameworks. Results. Recombinant vaccine platforms offer significant advantages for epidemic preparedness through rapid adaptability, standardized production, and strong safety profiles. Nonetheless, challenges remain in manufacturing scalability, cold-chain logistics, regulatory harmonization, and equitable global access. Global initiatives such as the CEPI, WHO-led programs, BARDA, and regional manufacturing networks exemplify this collaborative approach, while regulatory mechanisms have proven to be essential to timely vaccine deployment. Conclusions. Recombinant vaccines have redefined preparedness by coupling scientific innovation with operational agility. Strengthening global coordination, regional production capacity, and public trust is essential to ensure that technological progress translates into equitable and effective public health impacts. Full article
(This article belongs to the Special Issue Developing Recombinant Vaccines and Immunotherapy Strategies for Emerging Viral Diseases)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop